Stable coronary artery disease patients with type 2 diabetes
Conditions
Interventions
Sitagliptn
Sulfonylurea
Sponsors
Kanagawa PTCA Conference
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with type 2 diabetes 2)6.1%<=HbA1c <9.0% (JDS) or 6.5%<=HbA1c <9.4% (NGSP) 3)Stable coronary artery disease
Exclusion criteria
Exclusion criteria: 1)Patients with type 1diabetes 2)Patients with ACS 3)patients with contraindication of antiplatelet drug 4)Patients with severe ketosis, diabetic coma or precoma within 6 months 5)Patients with severe infections, before or after operation, or serious trauma . 6)Patients with moderate renal dysfunction (sCr: male>1.5mg/dl, female>1.3mg/dl) 7)Patients who are pregnant, breast-feeding and/or intention to become pregnant 8)Patients with allergy against sitagliptin 9)Other patients determined to be inappropriate by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in plaque volume using Intravascular Ultrasound (IVUS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in plaque composition using Integrated Backscatter Intravascular Ultrasound (IB-IVUS), and change in lipids and glucose markers, and hs-CRP | — |
Countries
Japan
Contacts
Public ContactTsuyoshi Nozue
Yokohama Sakae Kyosai Hospital Division of Cardiology, Department of Internal Medicine
Outcome results
None listed